| Philadelphia chromosome positive chronic myelogenous leukemia
Iclusig vs Sprycel
Side-by-side clinical, coverage, and cost comparison for philadelphia chromosome positive chronic myelogenous leukemia.Deep comparison between: Iclusig vs Sprycel with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSprycel has a higher rate of injection site reactions vs Iclusig based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sprycel but not Iclusig, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Iclusig
Sprycel
At A Glance
Oral
Once daily
BCR::ABL kinase inhibitor
Oral
Once daily
BCR-ABL/SRC kinase inhibitor
Indications
- Leukemia, Myelomonocytic, Chronic
- Philadelphia chromosome positive chronic myelogenous leukemia
- Philadelphia chromosome positive chronic myelogenous leukemia
- B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
Dosing
Philadelphia chromosome positive chronic myelogenous leukemia 45 mg orally once daily; reduce to 15 mg once daily upon achievement of <=1% BCR::ABL IS.
AP-CML, BP-CML 45 mg orally once daily.
Newly diagnosed Ph+ ALL 30 mg orally once daily in combination with chemotherapy; reduce to 15 mg once daily upon achievement of MRD-negative CR at the end of induction.
Ph+ ALL (monotherapy, T315I-positive or no other KI indicated) 45 mg orally once daily.
Philadelphia chromosome positive chronic myelogenous leukemia (adults) Chronic phase: 100 mg orally once daily; accelerated or blast phase: 140 mg orally once daily. Tablets must be swallowed whole, with or without food.
B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 (adults) 140 mg orally once daily, swallowed whole with or without food.
Philadelphia chromosome positive chronic myelogenous leukemia, B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 (pediatric patients >=1 year) Weight-based once daily: 40 mg (10 to <20 kg), 60 mg (20 to <30 kg), 70 mg (30 to <45 kg), 100 mg (>=45 kg); Ph+ ALL pediatric patients receive SPRYCEL in combination with chemotherapy for up to 2 years.
Contraindications
—
—
Adverse Reactions
Most common (>20%) Rash, arthralgia, abdominal pain, fatigue, headache, constipation, hypertension, dry skin, hepatotoxicity, fluid retention and edema, pyrexia, pancreatitis/lipase elevation, nausea, hemorrhage, anemia, arterial occlusive events, cardiac arrhythmias
Serious Arterial occlusive events, venous thromboembolic events, heart failure, hepatotoxicity, hypertension, pancreatitis, neuropathy, ocular toxicity, hemorrhage, fluid retention, cardiac arrhythmias, myelosuppression, tumor lysis syndrome, reversible posterior leukoencephalopathy syndrome, impaired wound healing, gastrointestinal perforation
Postmarketing Thrombotic microangiopathy, hyperthyroidism, gastrointestinal perforation, fistula, dehydration, reversible posterior leukoencephalopathy syndrome, severe cutaneous reactions (erythema multiforme, Stevens-Johnson syndrome), impaired wound healing, panniculitis, arterial aneurysms/dissections/rupture
Most common (>=10%) Fluid retention, pleural effusion, superficial localized edema, diarrhea, headache, musculoskeletal pain, rash, fatigue, nausea, dyspnea, hemorrhage, abdominal pain
Serious Myelosuppression, bleeding-related events, fluid retention, cardiovascular toxicity, pulmonary arterial hypertension, QT prolongation, severe dermatologic reactions, tumor lysis syndrome, hepatotoxicity
Postmarketing Hepatitis B virus reactivation, atrial fibrillation/atrial flutter, interstitial lung disease, chylothorax, Stevens-Johnson syndrome, nephrotic syndrome, thrombotic microangiopathy, hepatotoxicity
Pharmacology
Ponatinib is a kinase inhibitor that inhibits the tyrosine kinase activity of ABL and T315I mutant ABL, as well as VEGFR, PDGFR, FGFR, EPH receptor, and SRC family kinases, KIT, RET, TIE2, and FLT3, suppressing viability of cells expressing native or mutant BCR::ABL including T315I.
Dasatinib is a multi-targeted kinase inhibitor that at nanomolar concentrations inhibits BCR-ABL, SRC-family kinases (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRbeta, and can overcome imatinib resistance arising from BCR-ABL kinase domain mutations, activation of SRC-family signaling pathways, or multi-drug resistance gene overexpression.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Iclusig
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Sprycel
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Iclusig
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Sprycel
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Iclusig
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Sprycel
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Chronic Myeloid Leukemia (C.M.L.) - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Chronic Myeloid Leukemia (C.M.L.) - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IclusigView full Iclusig profile
SprycelView full Sprycel profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.